How we diagnose and treat deep vein thrombosis

Blood

Volumn 99, Issue 9, 2002, Pages 3102-3110

  Hirsh, Jack ^a,b   Lee, Agnes Y Y ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; COMORBIDITY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; ECHOGRAPHY; HUMAN; HYPERCOAGULABILITY; PHLEBOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TREATMENT PLANNING; ULTRASOUND; VALIDATION PROCESS;

EID: 0036565886     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3102     Document Type: Review

References (55)

1. Does this patient have deep vein thrombosis?
2. Accuracy of clinical assessment of deep-vein thrombosis
3. Value of assessment of pretest probability of deep-vein thrombosis in clinical management
4. Thrombosis in the emergency department: Use of a clinical diagnosis model to safely avoid the need for urgent radiological investigation
5. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis
6. A randomized trial in patients with suspected DVT comparing a D-dimer/clinical probability strategy to clinical probability, prior to ultrasound imaging. D-dimer safely reduces the need for diagnostic imaging
7. Use of a simplified clinical scoring system and D-dimer testing can reduce the requirement for radiology in the exclusion of deep vein thrombosis by over 20%
8. The role of-venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism
9. Noninvasive diagnosis of deep venous thrombosis
10. Laboratory diagnosis of venous thromboembolism
11. The value of rapid D-dimer testing combined with structured clinical evaluation for the diagnosis of deep vein thrombosis
12. SimpliRED D-dimer can reduce the diagnostic tests in suspected deep vein thrombosis
13. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing
14. Effective and safe practical diagnosis of deep vein thrombosis in 811 patients referred to non-academic teaching hospitals; the PRADIA Study
15. The optimal diagnostic management strategy in patients with suspected deep vein thrombosis
16. D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: Prospective cohort study
17. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound
18. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
19. The management of thrombosis in the antiphospholipid-antibody syndrome
20. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis
21. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
22. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
23. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
24. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
25. Low-molecular-weight heparins
26. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial
27. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
28. Managing oral anticoagulant therapy
29. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
30. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis
31. Hemorrhagic complications of anticoagulant treatment
32. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
33. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
34. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
35. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group
36. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
37. Prevention and treatment of postphlebitic syndrome: Results of a 3-part study
38. Deep venous thrombosis: Longitudinal study with duplex US
39. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis
40. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial
41. Thrombosis in pregnancy
42. Inherited thrombophilia and fetal loss
43. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
44. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
45. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hipfracture surgery
46. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
47. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement for the AstraZenca Arthroplasty Study Group. A phase 2 dose-finding study
48. Thrombolytic therapy for venous thromboembolism
49. Approach to the patient with venous thromboembolism. Treatment with thrombolytic agents
50. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism
51. Short-and long-term results after thrombolytic treatment of deep venous thrombosis
52. Vena caval filters: A comprehensive review
53. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
54. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism
55. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone